An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Vivani Medical says it has finished enrolling patients in a clinical trial testing a semaglutide implant, and it also announced a deal with Novo Nordisk, the big maker of semaglutide drugs. In plain terms, the company has recruited enough people to move forward with testing its device that would deliver semaglutide over time, and it has struck some kind of commercial or development agreement with the pharmaceutical company that makes the best-known semaglutide medicines. Semaglutide is the active ingredient in drugs like Ozempic and Wegovy. It’s a lab-made version of a hormone your gut releases after you eat that helps tell your brain you’re full and slows how fast food leaves your stomach. In medicine, semaglutide is used to help control blood sugar in diabetes and to help with weight loss. An “implant” in this context means a small device placed under the skin that would slowly release the drug over weeks or months, instead of people taking weekly injections. The news here is about trial enrollment and a business deal, not final proof the implant works. Completing enrollment just means the study has recruited the planned number of participants; it doesn’t mean results are available yet. The announcement doesn’t say how many people were enrolled, how long the implant releases the drug, or what outcomes the trial will measure. The Novo Nordisk deal suggests the implant uses semaglutide supplied or licensed from them, or that the companies will cooperate on development or commercialization, but the specific terms and impact aren’t detailed in the snippet. Why this could matter is practical: if an implant safely and reliably delivers semaglutide, it could simplify life for people who now need weekly injections. Fewer injections could mean fewer missed doses and steadier drug levels in the body, which might improve how well the drug works or reduce side effects tied to peaks and troughs. For people using semaglutide for diabetes or weight management, a long-acting implant could be more convenient and less visible than frequent shots. There are important caveats. An implant is a medical procedure and carries risks like infection, device migration, or the need for removal. We don’t yet have trial results showing the implant’s safety or effectiveness compared with standard injections. The deal with Novo Nordisk does not guarantee regulatory approval or broad availability. People should not assume this option is ready for patients until results are published and regulators review them. Bottom line: Vivani has reached a milestone by filling its trial and partnering with Novo Nordisk, but we still need actual study results to know whether a semaglutide implant is safe, effective, and better than current options.
Source: foreignpolicyjournal.com